WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Ian Smith Biography and Net Worth

COO of Vertex Pharmaceuticals

Ian F. Smith is Executive Chair of our Board and has served as a member of our board of directors since April 2020 and served as a consultant to us since February 2020. Mr. Smith currently serves as director and Executive Chair of the board of ViaCyte, Inc., and as a director of the board of AavantiBio, both private biotechnology companies. He is also a member of the Board of Foghorn Therapeutics, a public biotechnology company, and is a Senior Advisor to Bain Capital Life Sciences. Between 2001 and 2019, Mr Smith served as Executive Vice President and Chief Operating Officer, and Chief Financial Officer at Vertex Pharmaceuticals, a public biotechnology company.

He received a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK). Mr. Smith is qualified to serve on our board of directors because of his more than 25 years of finance and broad operating experience for public companies in the biopharmaceutical industry.

What is Ian F. Smith's net worth?: The estimated net worth of Ian F. Smith is at least $27.84 million as of June 29th, 2018. Mr. Smith owns 70,074 shares of Vertex Pharmaceuticals stock worth more than $27,838,298 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Smith may own. Learn More about Ian F. Smith's net worth.
How do I contact Ian F. Smith?: The corporate mailing address for Mr. Smith and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Ian F. Smith's contact information.
Has Ian F. Smith been buying or selling shares of Vertex Pharmaceuticals?: Ian F. Smith has not been actively trading shares of Vertex Pharmaceuticals during the last ninety days. Most recently, Ian F. Smith sold 23,375 shares of the business's stock in a transaction on Friday, June 29th. The shares were sold at an average price of $166.30, for a transaction totalling $3,887,262.50. Following the completion of the sale, the chief operating officer now directly owns 70,074 shares of the company's stock, valued at $11,653,306.20. Learn More on Ian F. Smith's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Ian F. Smith Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/29/2018	Sell	23,375	$166.30	$3,887,262.50	70,074
6/22/2018	Sell	4,250	$160.00	$680,000.00	50,949
5/15/2018	Sell	217	$155.78	$33,804.26	46,699
5/11/2018	Sell	4,096	$155.00	$634,880.00
4/26/2018	Sell	85,093	$158.32	$13,471,923.76	68,745
11/6/2017	Sell	6,405	$150.00	$960,750.00
11/3/2017	Sell	2,155	$150.00	$323,250.00	43,043
10/31/2017	Sell	75,000	$145.06	$10,879,500.00	114,188
10/16/2017	Sell	2,125	$155.61	$330,671.25	118,013
8/7/2017	Sell	4,250	$155.39	$660,407.50	120,138
8/2/2017	Sell	2,155	$154.17	$332,236.35	118,043
7/21/2017	Sell	133,750	$160.98	$21,531,075.00	151,738
5/16/2016	Sell	202	$82.06	$16,576.12	112,999
2/3/2016	Sell	12,084	$90.84	$1,097,710.56	112,999
3/23/2015	Sell	6,042	$125.67	$759,298.14
9/30/2014	Sell	108,026	$112.68	$12,172,369.68
10/8/2012	Sell	44,787	$60.00	$2,687,220.00

Ian F. Smith Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $397.27

$386.49

$401.31

50 Day Range

MA: $470.41

$396.64

$516.74

2 Week Range

Now: $397.27

$377.85

$519.88

Volume

6,202,268 shs

Average Volume

1,238,190 shs

Market Capitalization

$102.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36